A Practical lens for Board Members - Will this PI Founder still be CEO by Series B? Most European life sciences funds back companies where the founding CEO is a first‑time scientific leader: a PI out of a top lab, an ex‑pharma director, sometimes a computational founder with limited management experience. Very few investment memos say, “And we expect to replace them before Series B.” Yet that’s exactly what happens in a lot of cases—not always for the wrong reasons, but often

Your first five hires will decide whether your “platform biotech” ever becomes more than a pitch deck. In the first 18 months you’re not building an org chart, you’re building an engine: one person who truly owns the platform, one who runs everything that isn’t science, one who turns data into a scalable system, an early regulatory voice to stop you tripping over yourself later, and a business partner who keeps capital and deals flowing.

On 23rd July, I’m officially launching Sharon Shields Consulting — a specialist consultancy focused on executive research, market mapping and talent intelligence for life sciences organisations across the UK, Europe and the US. I also partner with executive search consultancies who need deep, reliable research support for complex senior mandates.

Thoughts from the beach - Ageing, learning and seniorlytics! Last weekend, I spent a day at the beach with family and friends aged 6 to 70. The younger ones threw themselves into the sea and into sandcastle building—fearless, curious, and quick to learn from mistakes. The older adults contributed stories and thoughtful advice, grounding our fun in lived experience. Children are called “sponges” for good reason: their brains form up to a million new connections every second (H